Back to top

Our family, innovating health, for yours.

+44 (0)1622 851122

ask@bedfont.com

For more information about Bedfont's stance on Coronavirus and breath testing, click here.

Asthma Management

The National Institute for Clinical Excellence (NICE) is advising GPs to improve the accuracy of their diagnosis by using clinically proven breath testing, we have developed the NObreath® FeNO breath monitor, which has been clinically proven to aid in the diagnosis and management of asthma. NObreath® measures molecules of nitric oxides on the breath that are created by inflamed airways in patients suffering from asthma. The testing for these particles, known as fractional exhaled nitric oxide (FeNO) with NObreath® has been clinically proven to aid in the diagnosis and management of asthma by monitoring inflammation levels combined with inflammation reducing medicine such as corticosteroids; much like glucose tests and insulin does for diabetics. The test takes less than 30 seconds to perform and can be carried out by a trained clinician, or in some cases by the patients themselves.

image of the NObreath V2

Aids in the diagnosis & management of asthma.

image of the iCO

Fractional exhaled Nitric Oxide (FeNO) monitoring